Synonyms: CB-313 | Lysodren®
mitotane is an approved drug (FDA (1970), EMA (2004))
Compound class:
Synthetic organic
Comment: The molecular mechanism underlying mitotane's clinical effects is complex and poorly understood [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Lehmann TP, Wrzesiński T, Jagodziński PP. (2013)
The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells. Mol Med Rep, 7 (3): 893-900. [PMID:23254310] |
2. Libè R, Fratticci A, Bertherat J. (2007)
Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer, 14 (1): 13-28. [PMID:17395972] |